TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8980952

Group type: EXPERIMENTAL
Intervention: Method A (previous method of sputum induction)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Method B (separate collection of saliva and sputum)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Method A
Number of subjects: 11

Group type: COMPARATOR
Intervention: Method B
Number of subjects: 11
Study: 1641117

Group type: EXPERIMENTAL
Intervention: Well structured fragmented forms
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Poorly structured forms
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Asymmetrical stimuli
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Oblique condition
Number of subjects: 2

Group type: COMPARATOR
Intervention: Well structured forms
Number of subjects: 2
Study: 6562083

Group type: EXPERIMENTAL
Intervention: Directive patient education group
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study: 30317336

Group type: EXPERIMENTAL
Intervention: Single visit endodontic treatment (Group-I)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Multiple visit endodontic treatment (Group-II)
Number of subjects: 60
Study: 28615379

Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplements (LNS-PL) containing 250 μg I, 20 g/d, 118 kcal
Number of subjects: 4011

Group type: COMPARATOR
Intervention: Iron and folic acid (IFA; 60 mg Fe/d + 400 μg folic acid/d)
Number of subjects: 4011
Study: 24390403

Group type: EXPERIMENTAL
Intervention: KiVa antibullying program
Number of subjects: 7491
Study: 21810005

Group type: EXPERIMENTAL
Intervention: Cetirizine 20 mg once daily (dose‐increase group)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Olopatadine 5 mg twice daily (drug‐change group)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Cetirizine 10 mg once daily (initial treatment)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Skindex‐16 (Quality of Life assessment)
Number of subjects: 51
Study: 21118744

Group type: EXPERIMENTAL
Intervention: Test formulation of venlafaxine extended-release 75-mg capsules (fasting)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Reference formulation of venlafaxine extended-release 75-mg capsules (fasting)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Test formulation of venlafaxine extended-release 75-mg capsules (fed)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Reference formulation of venlafaxine extended-release 75-mg capsules (fed)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both formulations (fasting and fed)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Adverse events (both phases)
Number of subjects: 48
Study: 18946626

Group type: EXPERIMENTAL
Intervention: Neridronate 25 mg IM every 2 weeks
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Neridronate 12.5 mg IM every 4 weeks
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Neridronate 25 mg IM every 4 weeks
Number of subjects: 188

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Neridronate (all doses)
Number of subjects: 188
Study: 15908335

Group type: EXPERIMENTAL
Intervention: Stilamin 250 microg/h
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Stilamin 500 microg/h
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sandostatin 100 microg
Number of subjects: 20
Study: 12839518

Group type: EXPERIMENTAL
Intervention: GHQ‐12
Number of subjects: 1808
Study: 10410404

Group type: EXPERIMENTAL
Intervention: Hyperbaric tetracaine (2.0 mL of 0.5% tetracaine in 5% dextrose)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Isobaric tetracaine (2.0 mL of 0.5% tetracaine in cerebrospinal fluid)
Number of subjects: 60
Study: 7552876

Group type: EXPERIMENTAL
Intervention: Local anesthesia during routine dental extractions
Number of subjects: 39
Study: 2188926

Group type: EXPERIMENTAL
Intervention: aclacinomycin-A (ACM-A, 100 mg/m2 or 85 mg/m2, every 3 weeks)
Number of subjects: 98

Group type: COMPARATOR
Intervention: 6-diazo-5-oxo-L-norleucine (DON; 50 mg/m2/day for 5 consecutive days every 4 weeks)
Number of subjects: 98
Study: 7386656

Group type: EXPERIMENTAL
Intervention: Carbamazepine (Tegretol) 600-1600 mg/day
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Carbamazepine (Tegretol)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 30868176

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 187

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study: 27980028

Group type: EXPERIMENTAL
Intervention: Universal home visiting model employing a nurse-parent educator team
Number of subjects: 244

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 244
Study: 26042920

Group type: EXPERIMENTAL
Intervention: Large plate (12-inch)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Small plate (8-inch)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Intuitive eating levels
Number of subjects: 137
Study: 23377392

Group type: EXPERIMENTAL
Intervention: Efinaconazole 10% solution (with or without semiocclusion)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Efinaconazole 5% solution
Number of subjects: 135

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 135
Study: 21113661

Group type: EXPERIMENTAL
Intervention: WALC‐S (motivational intervention)
Number of subjects: 97

Group type: COMPARATOR
Intervention: TAC (time and attention control group)
Number of subjects: 97
Study: 19534587

Group type: EXPERIMENTAL
Intervention: Sodium tanshinone IIA sulfonate (STS) 60 mg day(-1) injections for 13 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo injections for 13 days
Number of subjects: 16
Study: 17332003

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 15375791

Group type: EXPERIMENTAL
Intervention: Overweight subjects
Number of subjects: 62

Group type: COMPARATOR
Intervention: Normal weight subjects
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Adiponectin levels
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Ratio of adiponectin and %BF
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Correlation of adiponectin with insulin sensitivity
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Adiponectin and hs‐CRP levels
Number of subjects: 62
Study: 11252522

Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics
Number of subjects: 0
Study: 9726499

Group type: EXPERIMENTAL
Intervention: Self instructional CD‐ROM tutorial program
Number of subjects: 27

Group type: COMPARATOR
Intervention: Conventional classroom demonstration
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Combination of both methods
Number of subjects: 27
Study: 9505987

Group type: EXPERIMENTAL
Intervention: 50 mg venlafaxine tablet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 50 mg venlafaxine tablet with food
Number of subjects: 0

Group type: COMPARATOR
Intervention: 50 mg venlafaxine solution
Number of subjects: 0
Study: 2036242

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus radiotherapy (total nodal or involved field irradiation)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 118
Study: 6260873

Group type: EXPERIMENTAL
Intervention: Antithymocyte globulin
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Phytohemagglutinin
Number of subjects: 38

Group type: COMPARATOR
Intervention: Seropositive controls
Number of subjects: 38

Group type: COMPARATOR
Intervention: Seronegative controls
Number of subjects: 38
Study: 30088663

Group type: EXPERIMENTAL
Intervention: ACT-246475 1 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: ACT-246475 2 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: ACT-246475 4 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: ACT-246475 8 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: ACT-246475 16 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: ACT-246475 32 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 28854980

Group type: EXPERIMENTAL
Intervention: Financial stress
Number of subjects: 1047

Group type: EXPERIMENTAL
Intervention: Smoking-induced deprivation
Number of subjects: 1047

Group type: EXPERIMENTAL
Intervention: Financial stress and deprivation association
Number of subjects: 1047

Group type: EXPERIMENTAL
Intervention: Motivation to quit
Number of subjects: 1047
Study: 26363128

Group type: EXPERIMENTAL
Intervention: CNI-free immunosuppression with everolimus and mycophenolic acid
Number of subjects: 200

Group type: COMPARATOR
Intervention: Reduced-exposure CNI with concomitant everolimus
Number of subjects: 200
Study: 23477375

Group type: EXPERIMENTAL
Intervention: Safety guidewire (SGW)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No safety guidewire (SGW)
Number of subjects: 40
Study: 21979114

Group type: EXPERIMENTAL
Intervention: Acupuncture + Pulmonary Rehabilitation (PR)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Pulmonary Rehabilitation (PR)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 60
Study: 18456226

Group type: EXPERIMENTAL
Intervention: Laparoscopic hysterectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vaginal hysterectomy
Number of subjects: 0
Study: 17158418

Group type: EXPERIMENTAL
Intervention: Postprandial insulinemic response
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Postprandial glycemic response
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Low breakfast energy intake (EI)
Number of subjects: 28
Study: 12667149

Group type: EXPERIMENTAL
Intervention: Iron cooking pots
Number of subjects: 322

Group type: COMPARATOR
Intervention: Aluminium cooking pots
Number of subjects: 322
Study: 10878651

Group type: EXPERIMENTAL
Intervention: Iron supplementation and deworming in the study area
Number of subjects: 458
Study: 8907258

Group type: EXPERIMENTAL
Intervention: Dyclonine (40 ml enema)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 10
Study: 1833834

Group type: EXPERIMENTAL
Intervention: Isradipine 2.5 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isradipine 5.0 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isradipine 1.25 mg twice daily
Number of subjects: 0
Study: 6126425

Group type: EXPERIMENTAL
Intervention: Co-trimoxazole injections
Number of subjects: 60

Group type: COMPARATOR
Intervention: PCPL injections
Number of subjects: 60
Study: 31973094

Group type: EXPERIMENTAL
Intervention: PNF-ATSS condition
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: PNF-Only condition
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control+ATSS condition
Number of subjects: 70
Study: 30762754

Group type: EXPERIMENTAL
Intervention: SPT and SMV (SPT-SMV)
Number of subjects: 37

Group type: COMPARATOR
Intervention: SPT
Number of subjects: 37
Study: 26519049

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 148
Study: 25656161

Group type: EXPERIMENTAL
Intervention: Working memory training (n-back training)
Number of subjects: 0
Study: 24928479

Group type: EXPERIMENTAL
Intervention: Modafinil (200mg/day)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Escitalopram (20mg/day)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Modafinil + Escitalopram (200+20mg/day)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo (0mg/day)
Number of subjects: 64
Study: 22492091

Group type: EXPERIMENTAL
Intervention: Exenatide (10 μg, SC)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 19082719

Group type: EXPERIMENTAL
Intervention: Transnasal endoscopy (TN)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Transoral endoscopy (TO)
Number of subjects: 200
Study: 17766093

Group type: EXPERIMENTAL
Intervention: Levetiracetam (1500 mg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 15138674

Group type: EXPERIMENTAL
Intervention: Respiratory physiotherapy
Number of subjects: 81

Group type: COMPARATOR
Intervention: Suction
Number of subjects: 81
Study: 11775405

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 0
Study: 9853771

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: S-adenosylmethionine
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Combination of ursodeoxycholic acid and S-adenosylmethionine
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (vitamin)
Number of subjects: 32
Study: 7859801

Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg daily for 2 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (matched)
Number of subjects: 0
Study: 2735626

Group type: EXPERIMENTAL
Intervention: Zidovudine, 250 mg orally every 4 hours
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Zidovudine, 0.5 mg/kg body weight intravenously every 4 hours
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Zidovudine, 2.5 mg/kg intravenously every 4 hours
Number of subjects: 41

Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: All treatment groups (including zidovudine and placebo)
Number of subjects: 41
Study: 31788741

Group type: EXPERIMENTAL
Intervention: Lenalidomide maintenance (n=19)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Observation (n=21)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Induction therapy (VMP)
Number of subjects: 85
Study: 31670026

Group type: EXPERIMENTAL
Intervention: Robot-based drama intervention
Number of subjects: 26

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 26
Study: 28129949

Group type: EXPERIMENTAL
Intervention: SMS text message intervention (daily reminders to monitor RMC)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Control group (no SMS messages)
Number of subjects: 244
Study: 26596540

Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy for chest pain (CBT‐CP)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 126
Study: 24334181

Group type: EXPERIMENTAL
Intervention: Tenofovir-emtricitabine (TDF/FTC)
Number of subjects: 1813

Group type: EXPERIMENTAL
Intervention: Abacavir-lamivudine (ABC/3TC)
Number of subjects: 1813

Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV)
Number of subjects: 1813

Group type: COMPARATOR
Intervention: Atazanavir/ritonavir (ATV/r)
Number of subjects: 1813

Group type: EXPERIMENTAL
Intervention: All treatment arms
Number of subjects: 1813
Study: 21704807

Group type: EXPERIMENTAL
Intervention: Multiband mucosectomy (MBM)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Endoscopic resection-cap (ER-cap)
Number of subjects: 84
Study: 19880935

Group type: EXPERIMENTAL
Intervention: Internet-based treatment with therapist guidance and online group discussions
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Pure bibliotherapy
Number of subjects: 235

Group type: COMPARATOR
Intervention: Waiting list
Number of subjects: 235
Study: 16830792

Group type: COMPARATOR
Intervention: MMP-9 levels and activity in decompensated MI patients (group B)
Number of subjects: 55

Group type: COMPARATOR
Intervention: MMP-2 levels and activity in decompensated MI patients (group B)
Number of subjects: 55
Study: 14553874

Group type: EXPERIMENTAL
Intervention: Bypass surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Angioplasty with primary stenting
Number of subjects: 0
Study: 11120521

Group type: EXPERIMENTAL
Intervention: Pregestational diabetes mellitus requiring insulin therapy
Number of subjects: 1220

Group type: EXPERIMENTAL
Intervention: Chronic hypertension
Number of subjects: 1220

Group type: COMPARATOR
Intervention: Control group (healthy women)
Number of subjects: 1220
Study: 10086081

Group type: EXPERIMENTAL
Intervention: Tamoxifen (TMX)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Clomiphene citrate (CC)
Number of subjects: 87
Study: 8317684

Group type: EXPERIMENTAL
Intervention: S-(+)-ketamine 1 mg/kg
Number of subjects: 40

Group type: COMPARATOR
Intervention: ketamine-racemat 2 mg/kg
Number of subjects: 40
Study: 3743626

Group type: EXPERIMENTAL
Intervention: Cimetidine 1200 mg/day
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Digoxin 0.75 mg i.v. with cimetidine
Number of subjects: 6
Study: 30340182

Group type: EXPERIMENTAL
Intervention: Nap (120-min polysomnographically monitored sleep opportunity), N=17
Number of subjects: 32

Group type: COMPARATOR
Intervention: Wake (wakefulness), N=15
Number of subjects: 32
Study: 27289411

Group type: EXPERIMENTAL
Intervention: Baseline leptin
Number of subjects: 2330

Group type: EXPERIMENTAL
Intervention: Change from baseline leptin
Number of subjects: 2330

Group type: EXPERIMENTAL
Intervention: Baseline adiponectin
Number of subjects: 2330

Group type: EXPERIMENTAL
Intervention: Baseline tumor necrosis factor α (TNF‐α)
Number of subjects: 2330

Group type: EXPERIMENTAL
Intervention: Change from baseline TNF‐α
Number of subjects: 2330

Group type: EXPERIMENTAL
Intervention: Baseline C‐reactive protein (CRP)
Number of subjects: 2330

Group type: EXPERIMENTAL
Intervention: Change from baseline CRP
Number of subjects: 2330

Group type: EXPERIMENTAL
Intervention: Change from baseline monocyte chemoattractant protein‐1
Number of subjects: 2330

Group type: EXPERIMENTAL
Intervention: Change from baseline IL‐6
Number of subjects: 2330
Study: 25103183

Group type: EXPERIMENTAL
Intervention: Stop My Smoking (SMS) USA mHealth program
Number of subjects: 164
Study: 23227470

Group type: EXPERIMENTAL
Intervention: 40 mg enoxaparin
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (sex- and age-matched medical ward patients)
Number of subjects: 15
Study: 20484759

Group type: EXPERIMENTAL
Intervention: Fitness training (F)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Walking program (W)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 128
Study: 17631387

Group type: EXPERIMENTAL
Intervention: Diaphragm, lubricant gel, and condoms
Number of subjects: 4948

Group type: COMPARATOR
Intervention: Condoms alone
Number of subjects: 4948
Study: 16044144

Group type: EXPERIMENTAL
Intervention: T-cell-depleted (TCD) donor marrow
Number of subjects: 410

Group type: COMPARATOR
Intervention: Unmanipulated donor marrow with methotrexate and cyclosporine (M/C)
Number of subjects: 410
Study: 12401617

Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg 1 h before surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10542928

Group type: EXPERIMENTAL
Intervention: External local infiltration anaesthesia
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Topical EMLA cream
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Topical AMETOP gel
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Topical intranasal cocaine (administered to all groups)
Number of subjects: 54
Study: 7598276

Group type: EXPERIMENTAL
Intervention: APACHE II scoring for patients requiring prolonged ICU stay (14-84 days)
Number of subjects: 43

Group type: COMPARATOR
Intervention: APACHE II scoring for control group (ICU stay of 48 hours or less)
Number of subjects: 43
Study: 2358837

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with cyclophosphamide 4.5 to 5.25 g/m2, etoposide 750 to 1,200 mg/m2, and cisplatin 120 to 180 mg/m2 (CVP)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with cyclophosphamide, etoposide, and cisplatin
Number of subjects: 58
Study: 778990

Group type: EXPERIMENTAL
Intervention: Floctafenine 200 mg four times a day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 30566415

Group type: EXPERIMENTAL
Intervention: Brexpiprazole (0.25, 1, 2, 4 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brexpiprazole (flexible-dose 1-4 mg/d)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Number of subjects: 0
Study: 28272299

Group type: COMPARATOR
Intervention: Genetic group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-Genetic group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All participants
Number of subjects: 0
Study: 25923818

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided unilateral TAP block with 20 mL 7.5 mg/mL ropivacaine
Number of subjects: 16
Study: 23670744

Group type: EXPERIMENTAL
Intervention: BiCision
Number of subjects: 30

Group type: COMPARATOR
Intervention: UltraCision
Number of subjects: 30
Study: 21586838

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab (0.5 mg in 0.05 ml) monthly for 3 months
Number of subjects: 104

Group type: COMPARATOR
Intervention: Intravitreal bevacizumab (1.25 mg in 0.05 ml) monthly for 3 months
Number of subjects: 104

Group type: COMPARATOR
Intervention: Comparison of ranibizumab and bevacizumab
Number of subjects: 104
Study: 18298242

Group type: EXPERIMENTAL
Intervention: Single-session motivational enhancement intervention
Number of subjects: 220

Group type: COMPARATOR
Intervention: Assessment-only control group
Number of subjects: 220
Study: 16781216

Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 6500

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 6500
Study: 12669753

Group type: EXPERIMENTAL
Intervention: First-phoneme irregular word fillers (e.g., CHEF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Third-phoneme irregular word fillers (e.g., GLOW)
Number of subjects: 0
Study: 10731382

Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation program (Group 1, n = 58) for 8 weeks (24 sessions)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Normal daily physical activity (Group 2, n = 64)
Number of subjects: 122
Study: 9042560

Group type: EXPERIMENTAL
Intervention: Enoxaparin 40mg once daily for 21 days
Number of subjects: 179

Group type: COMPARATOR
Intervention: Placebo once daily for 21 days
Number of subjects: 179
Study: 1331558

Group type: EXPERIMENTAL
Intervention: Fentanyl 30 micrograms.kg‐1 (group F30)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Fentanyl 75 micrograms.kg‐1 (group F75)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Droperidol 0.25 mg.kg‐1 and fentanyl 5 micrograms.kg‐1 (group N)
Number of subjects: 25
Study: 3901663

Group type: EXPERIMENTAL
Intervention: 2-dose regimen of acetylsalicylic acid
Number of subjects: 8

Group type: COMPARATOR
Intervention: 3-dose regimen of acetylsalicylic acid
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Both 2-dose and 3-dose regimens of acetylsalicylic acid
Number of subjects: 8